A5027598490- SARS-CoV-2 and COVID-19 Research
- Immunotherapy and Immune Responses
- Multiple Sclerosis Research Studies
- vaccines and immunoinformatics approaches
- Peripheral Neuropathies and Disorders
- Polyomavirus and related diseases
- Viral-associated cancers and disorders
- Drug-Induced Adverse Reactions
- Tuberculosis Research and Epidemiology
- Animal Virus Infections Studies
- Immune Cell Function and Interaction
- Genomic variations and chromosomal abnormalities
- Genetic Mapping and Diversity in Plants and Animals
- Evolution and Genetic Dynamics
- Asthma and respiratory diseases
- Genetic Associations and Epidemiology
- Mast cells and histamine
- Bacillus and Francisella bacterial research
- Genetics, Bioinformatics, and Biomedical Research
- Pharmacovigilance and Adverse Drug Reactions
Queen Mary University of London
2021-2023
Barts Health NHS Trust
2023
Royal London Hospital
2023
Nemours Children’s Clinic
2017
The purpose of this study was to investigate the effect disease modifying therapies on immune response severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines in people with multiple sclerosis (MS).Four hundred seventy-three MS provided one or more dried blood spot samples. Information about coronavirus 2019 (COVID-19) and vaccine history, medical, drug history were extracted from questionnaires medical records. Dried spots eluted tested for antibodies SARS-CoV-2. Antibody...
Abstract Objective To investigate the effect of disease modifying therapies on serological response to SARS-CoV2 vaccines in people with multiple sclerosis Methods 473 from 5 centres provided one or more dried blood spot samples and questionnaires about COVID-19. Information drug history was extracted their medical records. Dried spots were eluted tested for antibodies receptor binding domain. Seropositivity expressed according validated cut-off indices. Antibody titers partitioned into...
People with MS treated anti-CD20 therapies and fingolimod often have attenuated responses to initial COVID-19 vaccination. However, uncertainties remain about the benefit of a 3rd (booster) vaccine in this group.PwMS without detectable IgG response following vaccines 1&2 were invited participate. Participants provided dried blood spot +/- venous sample 2-12 weeks 3. Humoral T cell SARS-CoV-2 spike protein nucleocapsid antigen measured.Of 81 participants, 79 sample, whom 38 also whole sample;...
The genetic architecture of Multiple Sclerosis (MS) susceptibility has been extensively assessed in populations European ancestry. Greater ancestral diversity analyses MS is needed to improve the utility risk scores, fine map causal variants underlying established associations, and thereby enhance identification drug targets. Here we report findings from a study an ancestrally-diverse United Kingdom-based cohort. Participants with were recruited via clinical sites, online platform, through...
Purpose Genetic studies of multiple sclerosis (MS) susceptibility and severity have focused on populations European ancestry. Studying MS genetics in other ancestral groups is necessary to determine the generalisability these findings. The genetic Association study individuals from Diverse Ancestral backgrounds with Multiple Sclerosis (ADAMS) project aims gather phenotypic data a large cohort ancestrally-diverse living UK. Participants Adults self-reported diverse backgrounds. Recruitment...
Background: People with multiple sclerosis (pwMS) treated certain disease-modifying therapies (DMTs) have attenuated IgG response following COVID-19 vaccination; however, the clinical consequences remain unclear. Objective: To report rates in pwMS according to vaccine serology. Methods: PwMS available (1) serology 2–12 weeks 2 and/or 3 and (2) data on infection/hospitalisation were included. Logistic regression was performed examine whether seroconversion vaccination predicted risk of...
The Duffy antigen receptor for chemokines (DARC) is an atypical that regulates pro-inflammatory cytokines. However, the role of DARC in asthma pathophysiology unknown.
Clinical trial populations do not fully reflect routine practice. The power of routinely collected data to inform clinical practice is increasingly recognised.The OPTIMISE:MS pharmacovigilance study a prospective, pragmatic observational study, conducted across 13 UK MS centres. Data were at the time visits. first participant was recruited on 24th May 2019; extracted 11th November 2021.2112 participants included (median age 44.0 years; 1570 (72%) female; 1981 (94%) relapsing-remitting MS)....
Background: Despite increasing evidence that Epstein–Barr virus (EBV) plays a causal role in MS, no treatments have been shown to reduce EBV turnover. We studied the effect of famciclovir on salivary shedding people with MS (NCT05283551) pilot, proof-of-concept study. Methods: People receiving natalizumab provided weekly saliva samples for 12 weeks before starting 500 mg twice daily weeks. Twelve were treatment and following treatment. A real-time qPCR Taqman assay was used detect DNA...
Abstract Background There is increasing evidence that Epstein-Barr virus (EBV) plays a causal role in MS. No treatments have been shown to reduce EBV turnover. We studied the effect of famciclovir on salivary shedding people with MS ( NCT05283551 ). Methods People receiving natalizumab provided weekly saliva samples for 12 weeks before starting Famciclovir 500mg bd. were treatment and following treatment. A real-time quantitative PCR Taqman assay targeted non-repeated sequence polymerase...
Abstract Background Uncertainties remain about the benefit of a 3rd COVID-19 vaccine for people with attenuated response to earlier vaccines. This is particular relevance multiple sclerosis (pwMS) treated anti-CD20 therapies and fingolimod, who have substantially reduced antibody responses initial course. Methods PwMS taking part in seroprevalence study without detectable IgG following vaccines 1&2 were invited participate. Participants provided dried blood spot +/-venous sample 2-12...
Background Attenuated vaccine response is a concern in people receiving immunosuppression. It unclear whether booster vaccinations improve immunity this context. Methods T-cell and antibody responses to Sars-COV-2 RBD (spike protein) were measured following third COVID-19 (v3) with MS who IgG seronegative after vaccines 1&2. Results 41 (30:11 female:male; mean age 45.6 years) included; 28 ocreli- zumab 6 fingolimod, the remainder on other immunosuppressants. Samples taken 4-8 weeks v3....